Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
LCZ696
Olmesartan
Placebo of LCZ696
Placebo of Olmesartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring hypertension,, LCZ696,, olmesartan
Eligibility Criteria
Inclusion Criteria:
- patients with mild to moderate hypertension, untreated or currently taking antihypertensive therapy
- treated patients (using antihypertensive drugs within 4 weeks prior to first visit) must have an office msSBP ≥ 145 mmHg and < 180 mmHg after washout epoch and after 4 weeks run-in epoch
- untreated patients (either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit) must have an offcie msSBP ≥ 150 mmHg and < 180 mmHg at screening and 1 week after screening and must have an office msSBP ≥ 145 mmHg and < 180 mmHg after 4 weeks run-in epoch
- patients must successfully complete ABPM and pass technical requirements to be qualified for randomization
Exclusion Criteria:
- Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)
- History of angioedema, drug-related or otherwise
- History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease (PKD), drug-induced hypertension
- Patients who previously entered a LCZ696 study and had been randomized or enrolled to receive active drug treatment
Sites / Locations
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
- Novartis Investigative Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
LCZ696 200 mg
Olmesartan 20 mg
Arm Description
Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
Outcomes
Primary Outcome Measures
Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)
Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The first 24-hour ABPM will be performed beginning at 24 hours prior to baseline visit and the second will be performed 24 hours prior to week 8 visit.
Secondary Outcome Measures
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)
Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The 24-hour ABPM measurements are performed beginning 24 hours prior to baseline and week 8 visits.
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Sitting blood pressure (BP) measurement will be taken at every visit from screening through end of study. For each participant at each visit, four separate sitting BP measurements will be obtained (with a full two minute interval between measurements) and averaged to obtain the mean
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
Sitting blood pressure (BP) measurement will be taken at every visit from screening through end of study. For each participant at each visit, four separate sitting BP measurements will be obtained (with a full two minute interval between measurements) and averaged to obtain the mean
Change From Baseline in Office Pulse Pressure
Mean sitting pulse pressure (msPP) will be calculated at screening through end of study at every visit. Mean sitting pulse pressure is calculated as msSBP-msDBP.
Number of Patients Achieving Successful Overall Blood Pressure Control
Successful overall blood pressure control is defined as both msSBP/msDBP <140/90 mmHg
Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control
Successful mean sitting systolic blood pressure control is defined as msSBP <140 mmHg
Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control
Successful mean sitting diastolic blood pressure control is defined as msDBP <90 mmHg
Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response
Successful mean sitting systolic blood pressure response is defined as msSBP <140 mmHg or a reduction ≥ 20 mmHg from baseline.
Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response
Successful mean sitting diastolic blood pressure response is defined as msDBP <90 mmHg or a reduction ≥10 mmHg from baseline.
Number of Patients With Total Adverse Events, Serious Adverse Events and Death
Number of patients with total adverse events, serious adverse events and death were reported.
Full Information
NCT ID
NCT01876368
First Posted
June 9, 2013
Last Updated
November 3, 2015
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT01876368
Brief Title
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Official Title
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
hypertension,, LCZ696,, olmesartan
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
376 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LCZ696 200 mg
Arm Type
Experimental
Arm Description
Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
Arm Title
Olmesartan 20 mg
Arm Type
Active Comparator
Arm Description
Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
LCZ696
Intervention Type
Drug
Intervention Name(s)
Olmesartan
Intervention Type
Drug
Intervention Name(s)
Placebo of LCZ696
Intervention Type
Drug
Intervention Name(s)
Placebo of Olmesartan
Primary Outcome Measure Information:
Title
Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)
Description
Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The first 24-hour ABPM will be performed beginning at 24 hours prior to baseline visit and the second will be performed 24 hours prior to week 8 visit.
Time Frame
baseline, 8 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)
Description
Twenty-four hour mean ambulatory blood pressure measurements (ABPM) will be performed at baseline and at end of study (week 8). The 24-hour ABPM measurements are performed beginning 24 hours prior to baseline and week 8 visits.
Time Frame
baseline, 8 weeks
Title
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Description
Sitting blood pressure (BP) measurement will be taken at every visit from screening through end of study. For each participant at each visit, four separate sitting BP measurements will be obtained (with a full two minute interval between measurements) and averaged to obtain the mean
Time Frame
baseline, 8 weeks
Title
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
Description
Sitting blood pressure (BP) measurement will be taken at every visit from screening through end of study. For each participant at each visit, four separate sitting BP measurements will be obtained (with a full two minute interval between measurements) and averaged to obtain the mean
Time Frame
baseline, 8 weeks
Title
Change From Baseline in Office Pulse Pressure
Description
Mean sitting pulse pressure (msPP) will be calculated at screening through end of study at every visit. Mean sitting pulse pressure is calculated as msSBP-msDBP.
Time Frame
baseline, 8 weeks
Title
Number of Patients Achieving Successful Overall Blood Pressure Control
Description
Successful overall blood pressure control is defined as both msSBP/msDBP <140/90 mmHg
Time Frame
8 weeks
Title
Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control
Description
Successful mean sitting systolic blood pressure control is defined as msSBP <140 mmHg
Time Frame
8 weeks
Title
Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control
Description
Successful mean sitting diastolic blood pressure control is defined as msDBP <90 mmHg
Time Frame
8 weeks
Title
Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response
Description
Successful mean sitting systolic blood pressure response is defined as msSBP <140 mmHg or a reduction ≥ 20 mmHg from baseline.
Time Frame
baseline, 8 weeks
Title
Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response
Description
Successful mean sitting diastolic blood pressure response is defined as msDBP <90 mmHg or a reduction ≥10 mmHg from baseline.
Time Frame
baseline, 8 weeks
Title
Number of Patients With Total Adverse Events, Serious Adverse Events and Death
Description
Number of patients with total adverse events, serious adverse events and death were reported.
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
patients with mild to moderate hypertension, untreated or currently taking antihypertensive therapy
treated patients (using antihypertensive drugs within 4 weeks prior to first visit) must have an office msSBP ≥ 145 mmHg and < 180 mmHg after washout epoch and after 4 weeks run-in epoch
untreated patients (either newly diagnosed or those patients with a history of hypertension but have not been taking any antihypertensive drugs for at least 4 weeks prior to first visit) must have an offcie msSBP ≥ 150 mmHg and < 180 mmHg at screening and 1 week after screening and must have an office msSBP ≥ 145 mmHg and < 180 mmHg after 4 weeks run-in epoch
patients must successfully complete ABPM and pass technical requirements to be qualified for randomization
Exclusion Criteria:
Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)
History of angioedema, drug-related or otherwise
History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease (PKD), drug-induced hypertension
Patients who previously entered a LCZ696 study and had been randomized or enrolled to receive active drug treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294-2041
Country
United States
Facility Name
Novartis Investigative Site
City
Fair Oaks
State/Province
California
ZIP/Postal Code
95628
Country
United States
Facility Name
Novartis Investigative Site
City
Hawaiian Gardens
State/Province
California
ZIP/Postal Code
90716
Country
United States
Facility Name
Novartis Investigative Site
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
Novartis Investigative Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Novartis Investigative Site
City
Orangevale
State/Province
California
ZIP/Postal Code
95662
Country
United States
Facility Name
Novartis Investigative Site
City
Westlake Village
State/Province
California
ZIP/Postal Code
91361
Country
United States
Facility Name
Novartis Investigative Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Novartis Investigative Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
Facility Name
Novartis Investigative Site
City
Conyers
State/Province
Georgia
ZIP/Postal Code
30094
Country
United States
Facility Name
Novartis Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Novartis Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60610
Country
United States
Facility Name
Novartis Investigative Site
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Novartis Investigative Site
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
Novartis Investigative Site
City
Belzoni
State/Province
Mississippi
ZIP/Postal Code
39038
Country
United States
Facility Name
Novartis Investigative Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39209
Country
United States
Facility Name
Novartis Investigative Site
City
New York
State/Province
New York
ZIP/Postal Code
10708
Country
United States
Facility Name
Novartis Investigative Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45246
Country
United States
Facility Name
Novartis Investigative Site
City
Oregon City
State/Province
Oregon
ZIP/Postal Code
97045
Country
United States
Facility Name
Novartis Investigative Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Novartis Investigative Site
City
Varnville
State/Province
South Carolina
ZIP/Postal Code
29944
Country
United States
Facility Name
Novartis Investigative Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23294
Country
United States
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Buenos Aires
ZIP/Postal Code
C1429BWN
Country
Argentina
Facility Name
Novartis Investigative Site
City
Ciudad Autonoma de Bs As
State/Province
Buenos Aires
ZIP/Postal Code
C1119ACN
Country
Argentina
Facility Name
Novartis Investigative Site
City
Ciudad Autonoma de Bs As
State/Province
Buenos Aires
ZIP/Postal Code
C1430AAQ
Country
Argentina
Facility Name
Novartis Investigative Site
City
Caba
State/Province
Capital Federal
ZIP/Postal Code
C1425FVH
Country
Argentina
Facility Name
Novartis Investigative Site
City
Posadas
State/Province
Misiones
ZIP/Postal Code
N3300AHX
Country
Argentina
Facility Name
Novartis Investigative Site
City
Buenos aires
ZIP/Postal Code
C1120AAC
Country
Argentina
Facility Name
Novartis Investigative Site
City
Corrientes
ZIP/Postal Code
W3400
Country
Argentina
Facility Name
Novartis Investigative Site
City
Guatemala City
ZIP/Postal Code
01001
Country
Guatemala
Facility Name
Novartis Investigative Site
City
Guatemala City
ZIP/Postal Code
01010
Country
Guatemala
Facility Name
Novartis Investigative Site
City
Quezon City
State/Province
Manila
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novartis Investigative Site
City
Manila
State/Province
Metro Manila
ZIP/Postal Code
1000
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1100
Country
Philippines
Facility Name
Novartis Investigative Site
City
Quezon City
ZIP/Postal Code
1102
Country
Philippines
Facility Name
Novartis Investigative Site
City
Manati
ZIP/Postal Code
00674
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
Ponce
ZIP/Postal Code
00716
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
Ponce
ZIP/Postal Code
00717
Country
Puerto Rico
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
101990
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
111539
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
117198
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Moscow
ZIP/Postal Code
129301
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saint Petersburg
ZIP/Postal Code
199106
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Saratov
ZIP/Postal Code
410012
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
St.- Petersburg
ZIP/Postal Code
197110
Country
Russian Federation
Facility Name
Novartis Investigative Site
City
Sevilla
State/Province
Andalucia
ZIP/Postal Code
41009
Country
Spain
Facility Name
Novartis Investigative Site
City
Centelles
State/Province
Cataluña
ZIP/Postal Code
08540
Country
Spain
Facility Name
Novartis Investigative Site
City
Hostalets de Balenya
State/Province
Cataluña
ZIP/Postal Code
08550
Country
Spain
Facility Name
Novartis Investigative Site
City
Alzira
State/Province
Comunidad Valenciana
ZIP/Postal Code
46600
Country
Spain
Facility Name
Novartis Investigative Site
City
Santiago de Compostela
State/Province
Galicia
ZIP/Postal Code
15706
Country
Spain
Facility Name
Novartis Investigative Site
City
Madrid
ZIP/Postal Code
28046
Country
Spain
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
We'll reach out to this number within 24 hrs